

Terry M Nolan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/487260/publications.pdf>

Version: 2024-02-01

119
papers

3,965
citations

136740

32
h-index

133063

59
g-index

120
all docs

120
docs citations

120
times ranked

4202
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving vaccination rates in older adults and at-risk groups: focus on pertussis. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 1-8.	1.4	10
2	Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. <i>Vaccine</i> , 2022, 40, 4008-4016.	1.7	12
3	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
4	Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 176-190.	1.4	6
5	Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial. <i>Vaccine</i> , 2021, 39, 1598-1608.	1.7	6
6	National predictors of influenza vaccine uptake in pregnancy: the FluMum prospective cohort study, Australia, 2012-2015. <i>Australian and New Zealand Journal of Public Health</i> , 2021, 45, 455-461.	0.8	9
7	A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study. <i>Vaccine</i> , 2021, 39, 6628-6636.	1.7	4
8	Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. <i>Vaccine</i> , 2020, 38, 2105-2114.	1.7	21
9	Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. <i>Vaccine</i> , 2020, 38, 2095-2104.	1.7	24
10	Role of Rotavirus Vaccination in Decline in Incidence of Type 1 Diabetes-Reply. <i>JAMA Pediatrics</i> , 2019, 173, 895.	3.3	0
11	Coding Error in Study of Rotavirus Vaccination and Type 1 Diabetes in Children. <i>JAMA Pediatrics</i> , 2019, 173, 894.	3.3	4
12	Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2940-2951.	1.4	18
13	Does rotavirus turn on type 1 diabetes?. <i>PLoS Pathogens</i> , 2019, 15, e1007965.	2.1	18
14	Association of Rotavirus Vaccination With the Incidence of Type 1 Diabetes in Children. <i>JAMA Pediatrics</i> , 2019, 173, 280.	3.3	97
15	Influenza and pertussis vaccination of women during pregnancy in Victoria, 2015-2017. <i>Medical Journal of Australia</i> , 2019, 210, 454-462.	0.8	34
16	Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 643-650.	1.1	6
17	The Safety of Influenza and Pertussis Vaccination in Pregnancy in a Cohort of Australian Mother-Infant Pairs, 2012-2015: The FluMum Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 402-408.	2.9	31
18	Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. <i>Vaccine</i> , 2019, 37, 1209-1218.	1.7	33

#	ARTICLE	IF	CITATIONS
19	Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. <i>Vaccine</i> , 2018, 36, 1908-1916.	1.7	17
20	Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth. <i>JAMA Pediatrics</i> , 2018, 172, 1045.	3.3	34
21	Immunization During Pregnancy: Impact on the Infant. <i>Paediatric Drugs</i> , 2017, 19, 313-324.	1.3	16
22	Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample. <i>Journal of Infection</i> , 2017, 74, 29-41.	1.7	102
23	Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults. <i>Open Forum Infectious Diseases</i> , 2017, 4, S322-S322.	0.4	3
24	Socioeconomic and health factors associated with kindergarten retention in Australian children. <i>Journal of Paediatrics and Child Health</i> , 2016, 52, 296-302.	0.4	3
25	Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study. <i>Vaccine</i> , 2016, 34, 230-236.	1.7	12
26	Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial. <i>Vaccine</i> , 2016, 34, 4991-4997.	1.7	11
27	Deep sequence characterisation of a divergent HPIV-4a from an adult with prolonged influenza-like illness. <i>Virology Reports</i> , 2015, 5, 19-28.	0.4	0
28	Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, e80-e89.	2.9	32
29	Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1379-1384.	1.1	4
30	Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study. <i>Vaccine</i> , 2015, 33, 5217-5224.	1.7	37
31	Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. <i>Vaccine</i> , 2015, 33, 4437-4445.	1.7	28
32	Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. <i>Vaccine</i> , 2015, 33, 2485-2492.	1.7	45
33	Pertussis control: where to now?. <i>Medical Journal of Australia</i> , 2014, 200, 306-307.	0.8	4
34	Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 280-289.	1.4	23
35	FluMum: a prospective cohort study of mother-infant pairs assessing the effectiveness of maternal influenza vaccination in prevention of influenza in early infancy. <i>BMJ Open</i> , 2014, 4, e005676-e005676.	0.8	14
36	Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 194-200.	1.5	13

#	ARTICLE	IF	CITATIONS
37	Heterologous Prime-Boost Vaccination Using an AS03B-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age. <i>Journal of Infectious Diseases</i> , 2014, 210, 1800-1810.	1.9	17
38	Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 545-557.	1.9	32
39	Detection of a divergent Parainfluenza 4 virus in an adult patient with influenza like illness using next-generation sequencing. <i>BMC Infectious Diseases</i> , 2014, 14, 275.	1.3	11
40	Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59A [®] -adjuvanted influenza vaccine in infants and young children. <i>Vaccine</i> , 2014, 32, 6146-6156.	1.7	45
41	Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 330-339.	1.5	18
42	A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine. <i>Infectious Diseases and Therapy</i> , 2013, 2, 1-13.	1.8	9
43	Three-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type b (Hib)â€™Neisseria meningitidis Serogroup C-tetanus Toxoid Conjugate Vaccine in Hib-primed Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 169-174.	1.1	9
44	Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 676-685.	1.5	18
45	The safety profile of <i>Haemophilus influenzae</i> type bâ€™<i>Neisseria meningitidis</i> serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 304-311.	1.4	11
46	Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of <i>Haemophilus influenzae</i> type b and <i>Neisseria meningitidis</i> serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1036-1041.	1.4	10
47	A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e15-e23.	1.1	13
48	Improving influenza vaccination coverage in pregnancy in <sc>M</sc>elbourne 2010â€™2011. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2012, 52, 334-341.	0.4	49
49	Household transmission of respiratory viruses â€™ assessment of viral, individual and household characteristics in a population study of healthy Australian adults. <i>BMC Infectious Diseases</i> , 2012, 12, 345.	1.3	16
50	Australia's contribution to global immunisation. <i>Australian and New Zealand Journal of Public Health</i> , 2012, 36, 564-569.	0.8	2
51	Influence of Contact Definitions in Assessment of the Relative Importance of Social Settings in Disease Transmission Risk. <i>PLoS ONE</i> , 2012, 7, e30893.	1.1	14
52	Usefulness of Published PCR Primers in Detecting Human Rhinovirus Infection. <i>Emerging Infectious Diseases</i> , 2011, 17, 296-298.	2.0	36
53	IMMEDIATE AND LONGER TERM IMMUNOGENICITY OF A SINGLE DOSE OF THE COMBINED HAEMOPHILLUS INFLUENZAE TYPE B-NEISSERIA MENINGITIDIS SEROGROUP C-TETANUS TOXOID CONJUGATE VACCINE IN PRIMED TODDLERS 12 TO 18 MONTHS OF AGE. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 340-342.	1.1	14
54	Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 190-196.	1.1	26

#	ARTICLE	IF	CITATIONS
55	Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study. <i>Influenza and Other Respiratory Viruses</i> , 2011, 5, 7-11.	1.5	10
56	Making sense of perceptions of risk of diseases and vaccinations: a qualitative study combining models of health beliefs, decision-making and risk perception. <i>BMC Public Health</i> , 2011, 11, 943.	1.2	96
57	Immunogenicity and Safety of <i>H influenzae</i> Type <i>N meningitidis</i> C/Y Conjugate Vaccine in Infants. <i>Pediatrics</i> , 2011, 127, e1375-e1385.	1.0	27
58	Panvax [®] : a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009. <i>Expert Review of Vaccines</i> , 2011, 10, 35-43.	2.0	6
59	Immunogenicity of a Monovalent 2009 Influenza A(H1N1) Vaccine in Infants and Children. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 37.	3.8	181
60	The Australian model of immunization advice and vaccine funding. <i>Vaccine</i> , 2010, 28, A76-A83.	1.7	32
61	Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. <i>Vaccine</i> , 2010, 28, 4411-4415.	1.7	11
62	Panvax febrile reactions not a predictor. <i>BMJ: British Medical Journal</i> , 2010, 341, c3714-c3714.	2.4	0
63	Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpile. <i>Medical Journal of Australia</i> , 2009, 191, 136-137.	0.8	7
64	Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic. <i>American Journal of Epidemiology</i> , 2009, 169, 1517-1524.	1.6	14
65	Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. <i>Influenza and Other Respiratory Viruses</i> , 2009, 3, 315-325.	1.5	32
66	Electroencephalographic abnormalities during sleep in children with developmental speech-language disorders: a case-control study. <i>Developmental Medicine and Child Neurology</i> , 2009, 51, 228-234.	1.1	18
67	Booster vaccination of toddlers with reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. <i>Vaccine</i> , 2009, 27, 2410-2413.	1.7	2
68	Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. <i>Vaccine</i> , 2008, 26, 4160-4167.	1.7	70
69	Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. <i>Vaccine</i> , 2008, 26, 6383-6391.	1.7	81
70	Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age. <i>Pediatrics</i> , 2008, 121, 508-516.	1.0	40
71	Climate transformation: the next revolution in public health?. <i>Journal of Public Health</i> , 2008, 30, 362-363.	1.0	0
72	Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus-Like Particle Vaccine. <i>Journal of Infectious Diseases</i> , 2007, 196, 1153-1162.	1.9	113

#	ARTICLE	IF	CITATIONS
73	A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. <i>Vaccine</i> , 2007, 25, 8487-8499.	1.7	48
74	DTPa-HBV-IPV vaccine for primary vaccination of infants. <i>Journal of Paediatrics and Child Health</i> , 2007, 43, 587-592.	0.4	7
75	Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women. <i>Pediatrics</i> , 2006, 118, 2135-2145.	1.0	439
76	Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine Administered Concomitantly With Diphtheria-Tetanus-Acellular Pertussis and Haemophilus influenzae Type B Vaccines to Children Less Than 2 Years of Age. <i>Pediatrics</i> , 2006, 118, e602-e609.	1.0	18
77	Cognitive and Executive Function 12 Years after Childhood Bacterial Meningitis: Effect of Acute Neurologic Complications and Age of Onset. <i>Journal of Pediatric Psychology</i> , 2004, 29, 67-81.	1.1	82
78	Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. <i>Vaccine</i> , 2004, 23, 14-20.	1.7	27
79	Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis. <i>Journal of Pediatrics</i> , 2004, 144, 351-357.	0.9	21
80	The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. <i>Communicable Diseases Intelligence Quarterly Report</i> , 2004, 28, 510-6.	0.6	22
81	Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. <i>Vaccine</i> , 2003, 21, 1224-1231.	1.7	43
82	A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. <i>Vaccine</i> , 2002, 20, 3130-3136.	1.7	96
83	Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. <i>Vaccine</i> , 2002, 21, 281-289.	1.7	58
84	Infectious Disease: Increases in vaccination coverage for children in child care, 1997 to 2000: an evaluation of the impact of government incentives and initiatives. <i>Australian and New Zealand Journal of Public Health</i> , 2002, 26, 58-64.	0.8	27
85	A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity. <i>Vaccine</i> , 2001, 19, 2127-2137.	1.7	16
86	Quality of hospital care for seriously ill children in less-developed countries. <i>Lancet</i> , The, 2001, 357, 106-110.	6.3	332
87	Laboratory enhanced surveillance for meningococcal disease in Victoria. <i>Journal of Paediatrics and Child Health</i> , 2001, 37, 7-12.	0.4	3
88	Vaccination: the facts, the fears, the future. <i>Australian and New Zealand Journal of Public Health</i> , 2001, 25, 189-189.	0.8	0
89	Adolescent hepatitis B immunisation-should it be the law?. <i>Australian and New Zealand Journal of Public Health</i> , 2001, 25, 230-233.	0.8	8
90	Randomised controlled trial of an educational strategy to increase school-based adolescent hepatitis B vaccination. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 298-304.	0.8	28

#	ARTICLE	IF	CITATIONS
91	Conjugate pneumococcal vaccines for non-Indigenous children in Australia. Medical Journal of Australia, 2000, 173, S54-7.	0.8	10
92	Immunisation uptake, services required and government incentives for users of formal day care. Australian and New Zealand Journal of Public Health, 1999, 23, 368-376.	0.8	21
93	Vaccine preventable diseases and immunisations: a qualitative study of mothers' perceptions of severity, susceptibility, benefits and barriers. Australian and New Zealand Journal of Public Health, 1998, 22, 441-446.	0.8	103
94	A combined liquid Hib (PRP-OMP), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: uncontrolled preliminary clinical trial of immunogenicity and reactogenicity. Vaccine, 1998, 16, 2085-2089.	1.7	1
95	The Melbourne House Dust Mite Study: Long-term efficacy of house dust mite reduction strategies. Journal of Allergy and Clinical Immunology, 1998, 101, 451-456.	1.5	51
96	School based bicycle safety education and bicycle injuries in children: a case-control study. Injury Prevention, 1998, 4, 22-27.	1.2	39
97	Prevalence of tuberculosis infection in Melbourne secondary school students. Medical Journal of Australia, 1998, 168, 106-110.	0.8	15
98	Home vaccination for children behind in their immunisation schedule: a randomised controlled trial. Medical Journal of Australia, 1998, 168, 487-490.	0.8	25
99	Measles-mumps-rubella and hepatitis B vaccination uptake in adolescents: a survey in metropolitan Melbourne. Medical Journal of Australia, 1998, 168, 546-549.	0.8	11
100	Childhood bacterial meningitis: Impact of age at illness and acute medical complications on long term outcome.. Journal of the International Neuropsychological Society, 1997, 3, 147-158.	1.2	56
101	Vaccination - is the evidence good enough to say there is no risk?. Medical Journal of Australia, 1997, 167, 559-559.	0.8	0
102	Walking to school and traffic exposure in Australian children. Australian and New Zealand Journal of Public Health, 1997, 21, 286-292.	0.8	70
103	Paediatric slow-speed non-traffic fatalities: Victoria, Australia, 1985-1995. Accident Analysis and Prevention, 1997, 29, 731-737.	3.0	13
104	A case-control study of child bicycle injuries: relationship of risk to exposure. Accident Analysis and Prevention, 1995, 27, 839-844.	3.0	19
105	Free-standing truck wheels dangerous to children. Medical Journal of Australia, 1995, 162, 499-501.	0.8	0
106	Attitudes of Victorian vaccine providers to pertussis vaccine. Medical Journal of Australia, 1994, 161, 295-299.	0.8	21
107	The child behaviour checklist in a Melbourne urban sample. Australian Psychologist, 1994, 29, 103-109.	0.9	12
108	Role of a children's hospital safety centre in injury control. Pediatrics International, 1993, 35, 223-228.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Community-Based Study of Mortality in Children with Epilepsy. <i>Epilepsia</i> , 1993, 34, 597-603.	2.6	116
110	New Concepts in the Management of Encopresis. <i>Pediatrics in Review</i> , 1993, 14, 447-451.	0.2	15
111	Australian Rules football injuries in children and adolescents. <i>Medical Journal of Australia</i> , 1993, 159, 301-306.	0.8	52
112	Proof of immunisation status required for school entry. <i>Medical Journal of Australia</i> , 1993, 159, 564-565.	0.8	3
113	Computer-assisted instruction in Australian medical schools. <i>Medical Journal of Australia</i> , 1993, 159, 175-176.	0.8	11
114	DT vaccine in place of DTP vaccine for children. <i>Medical Journal of Australia</i> , 1993, 159, 631-631.	0.8	9
115	Evaluation of the properties and reliability of a clinical severity scale for acute asthma in children. <i>Journal of Clinical Epidemiology</i> , 1992, 45, 71-76.	2.4	70
116	Revision, Replication and Neglect? Research on Maladjustment in Chronic Illness. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 1991, 32, 347-365.	3.1	101
117	Measles "eradication or procrastination?". <i>Medical Journal of Australia</i> , 1990, 152, 449-450.	0.8	5
118	CONTROLLED TRIAL OF SOCIAL WORK IN CHILDHOOD CHRONIC ILLNESS. <i>Lancet, The</i> , 1987, 330, 411-415.	6.3	19
119	Walking to school and traffic exposure in Australian children. <i>Australian and New Zealand Journal of Public Health</i> , 1977, 21, 286-292.	0.8	0